Caribou Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.445 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 47.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Details
| Name | Caribou Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 97 |
| Founded | 2011 |
| Ipo Date | 2021-07-23 |
| Ceo | Rachel Haurwitz |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US1420381089 |
| Cusip | 142038108 |
| Cik | 1619856 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Sriram Ryali M.B.A. | Chief Financial Officer |
| Barbara G. McClung Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Jennifer A. Doudna Ph.D. | Co-founder and Member of Scientific Advisory Board |
| Ryan Fischesser | Interim Principal Accounting Officer and Controller |
| Dr. Justin Skoble Ph.D. | Senior Vice President of Technical Operations |
| Reigin Zawadzki | Chief People Officer |
| Dr. Tina Albertson M.D., Ph.D. | Chief Medical Officer |
| Enrique Zudaire Ph.D. | Senior Vice President of Translational Research |
Contact
| Address | 2929 7th Street, Suite 105, Berkeley, California 94710, United States |
| Phone | 510 982 6030 |
| Website | https://cariboubio.com |